Cravit contains levofloxacin, a broad-spectrum bactericidal agent, and is registered in 11 countries with a footprint heavily concentrated across East and Southeast Asia. Travellers and expatriates moving through Japan, Vietnam, Thailand, Singapore, or South Korea are the most likely to encounter this brand on a pharmacy shelf or prescription, while the same molecule circulates under other brand names in much of the rest of the world.
Levofloxacin is used in the management of a range of bacterial infections, including bronchitis, community-acquired pneumonia, prostatitis, and certain ocular infections such as conjunctivitis. It is also referenced in protocols for tuberculosis and other respiratory infections. The structured indication section further down this page lists each registered use as recognised by national regulators in the markets where Cravit is sold; the indication set varies between formulations, since levofloxacin is produced both as a systemic preparation and as an ophthalmic preparation, reflected in the ophthalmologicals classification alongside the broader bactericidal class.
Cravit's regional concentration — China, Taiwan, Hong Kong, Malaysia, Indonesia, and Turkey are also among the registered markets — means a reader who has been prescribed Cravit in Asia may not see the same brand name when filling a prescription in Europe, North America, or Latin America. Levofloxacin itself, however, is widely available internationally under several other brand names, and other antibiotics within the same broad-spectrum bactericidal family are stocked in essentially every regulated pharmacy market.
Antibiotic therapy is highly individualised, depending on the suspected pathogen, the site of infection, and patient-specific factors. Anyone prescribed Cravit, or trying to identify a local equivalent while travelling, should rely on a healthcare provider and a local pharmacist to confirm the right product.
